304 related articles for article (PubMed ID: 19180481)
1. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.
Lafyatis R; Kissin E; York M; Farina G; Viger K; Fritzler MJ; Merkel PA; Simms RW
Arthritis Rheum; 2009 Feb; 60(2):578-83. PubMed ID: 19180481
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis.
van Laar JM
Arthritis Res Ther; 2010; 12(2):112. PubMed ID: 20441607
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
McQueen FM; Solanki K
Rheumatology (Oxford); 2015 May; 54(5):757-67. PubMed ID: 25573841
[TBL] [Abstract][Full Text] [Related]
4. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.
Melsens K; Vandecasteele E; Deschepper E; Badot V; Blockmans D; Brusselle G; De Langhe E; De Pauw M; Debusschere C; Decuman S; Deroo L; Houssiau F; Lenaerts J; Piette Y; Thevissen K; Vanthuyne M; Westhovens R; Wijnant S; De Keyser F; Smith V
Acta Clin Belg; 2018 Apr; 73(2):119-125. PubMed ID: 28891418
[TBL] [Abstract][Full Text] [Related]
5. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement.
Smith V; Piette Y; van Praet JT; Decuman S; Deschepper E; Elewaut D; De Keyser F
J Rheumatol; 2013 Jan; 40(1):52-7. PubMed ID: 23118116
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
7. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.
Bosello S; De Santis M; Lama G; Spanò C; Angelucci C; Tolusso B; Sica G; Ferraccioli G
Arthritis Res Ther; 2010; 12(2):R54. PubMed ID: 20338043
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
[TBL] [Abstract][Full Text] [Related]
10. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.
Smith V; Van Praet JT; Vandooren B; Van der Cruyssen B; Naeyaert JM; Decuman S; Elewaut D; De Keyser F
Ann Rheum Dis; 2010 Jan; 69(1):193-7. PubMed ID: 19103636
[TBL] [Abstract][Full Text] [Related]
12. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
13. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
[TBL] [Abstract][Full Text] [Related]
14. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin.
Daoussis D; Tsamandas AC; Liossis SN; Antonopoulos I; Karatza E; Yiannopoulos G; Andonopoulos AP
Arthritis Res Ther; 2012 Jun; 14(3):R145. PubMed ID: 22697462
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
16. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
[TBL] [Abstract][Full Text] [Related]
18. Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
Melsens K; De Keyser F; Decuman S; Brusselle G; De Pauw M; Deschepper E; De Wilde K; Elewaut D; Piette Y; Vandecasteele E; Smith V
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):148-151. PubMed ID: 27463733
[TBL] [Abstract][Full Text] [Related]
19. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
[TBL] [Abstract][Full Text] [Related]
20. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]